



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

28th February 2025

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received an Orders dated 27th February 2025 from Punjab State GST authorities & Rajasthan Commercial Tax Department raising total demand of Rs. 53,67,166 & Rs. 22,96,651 respectively. The relevant details to be disclosed are as under:

Sr no	Particulars	Details
1	Name of the authority	Excise and Taxation officer cum State Tax officer, Mohali Ward No.9, Mohali, Punjab Joint Commissioner, Office of Joint Commissioner, Commercial tax department, Circle -E, Zone -III, Jaipur
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 27 th February 2025 Tax of Rs. 28,29,239; Interest – 22,44,945 and Penalty of Rs. 2,92,982 (Total demand: Rs. 53,67,166) Tax of Rs.12,70,269; Interest – 8,82,645 and Penalty of Rs. 1,43,737 (Total demand: Rs. 22,96,651)
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	27 th February 2025
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand for FY 2020-21, largely on account of input tax credit related issues, including difference in GST credit mismatch between Company's GST returns and details reported by suppliers in their GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on financial operations of the Company. The Company is evaluating the demand order and will take appropriate actions in due course.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151